News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly ORION-2 with inclisiran in homozygous familial hypercholesterolaemia LDL cholesterol targets in stroke patients: where to?ODYSSEY OUTCOMES and stroke events Treat ischaemic stroke to target ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ACC.20 with the World Congress of Cardiology

Virtual Meeting 28-30 March

Polygenic risk, LDL and SBP
Inclisiran: Data for >3,600 patients
Evinacumab: Nearly halves LDL-C in HoFH
ODYSSEY HoFH: Alirocumab shows benefit

AHA Scientific Sessions 2019

16-18 November, Philadelphia, USA

ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI

Most viewed

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) EVOLVD trial in heart transplant recipients Pooled analyses confirm benefit of PCSK9 inhibitors on secondary lipid targets Treat ischaemic stroke to target VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a) LDL cholesterol goals go even lower in India

Most viewed

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Hot Topics

12th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum

Do we need to reconsider LDL cholesterol targets in stroke patients?

With insights from the Treat Stroke to Target trial, FOURIER and ODYSSEY OUTCOMES, the question is: what should be the LDL cholesterol targets in stroke patients?

Professor Pierre Amarenco (Bichat Hospital, University of Paris, France) puts the data into perspective

Watch the webcast

Professor Wouter Jukema (Leiden University Medical Center, The Netherlands) discusses findings from ODYSSEY OUTCOMES

Watch the webcast

From the Editors

LDL cholesterol targets in stroke patients: where to?

Professor Pierre Amarenco, Bichat Hospital, University of Paris, France, makes the case for reconsideration of LDL cholesterol targets to prevent stroke, based on evidence from recent trials.

Read the report

Other related reports:
Treat ischaemic stroke to target
Watch the webcast
ODYSSEY OUTCOMES and stroke events
Watch the webcast
PCSK9 inhibition: impact on stroke
Read the report
How low should LDL cholesterol be lowered after stroke?
Read the report